Target intelligence / Profile preview

IGF1R antisense intragenic noncoding RNA (commonly known as IRAIN) (IRAIN)

Target
IRAIN
Molecular classification
Long noncoding RNA (lncRNA), Antisense RNA, Noncoding gene product (not a protein-coding gene)
01

Overview

IRAIN is a long noncoding RNA transcribed antisense to the IGF1R gene from an intronic promoter. It is monoallelically expressed from the paternal chromosome and lacks protein-coding potential. IRAIN plays a critical role in epigenetic regulation by mediating chromatin looping between enhancer and promoter regions of IGF1R, thus influencing IGF1R transcription. Downregulation of IRAIN, as observed in multiple cancers, relieves its regulatory constraint on IGF1R, resulting in overexpression of IGF1R and enhanced activation of oncogenic signaling pathways such as PI3K/AKT. IRAIN’s unique regulatory function and disease correlation make it a subject of interest for potential lncRNA-based cancer therapies and as a biomarker for tumorigenesis.

Other names
IRAINIGF1R antisense intragenic noncoding RNAIGF1R antisense lncRNAlnc-IGF1R-1IRAIN lncRNA
02

Mechanism of action

Not a drug target itself. Modulation of IRAIN (e.g., upregulation via CRISPR or antisense approaches) *indirectly* downregulates IGF1R via transcriptional interference/competition. The “mechanism of action” relates to regulating IGF1R signaling indirectly, not direct pharmacological targeting.

03

Biological functions

Chromatin organization: IRAIN is involved in facilitating enhancer/promoter chromatin looping at the IGF1R locusEpigenetic regulation: Functions as an epigenetic regulator by *cis*-competition with IGF1R for transcriptional machinery, modulating IGF1R expressionImprinting regulation: Expressed exclusively from the paternal allele (monoallelic, imprinted expression)Tumor suppression: Functions as a putative tumor suppressor by inhibiting IGF1R expression and associated signaling
04

Disease associations

Cancer (notably acute myeloid leukemia, breast cancer, non-small-cell lung cancer, and pancreatic cancer)Potential tumor suppressor whose loss or downregulation is associated with tumorigenesis and increased IGF1R signaling
05

Safety considerations

As a lncRNA, therapeutic targeting poses challenges in specificity, delivery, and off-target modulation. There are no established “safety concerns” specifically for IRAIN itself, but general challenges in lncRNA-targeted therapies apply.
06

Interacting drugs

None directly. IRAIN is not a direct drug target. However, research is ongoing into drugs and gene therapy approaches that might modulate its expression (e.g., CRISPR-mediated upregulation), but these are experimental and not established drug interactions.
07

Biomarkers

Decreased IRAIN expression is associated with poor prognosis or more aggressive cancer phenotypes, particularly in AML and breast cancer, suggesting potential as a *prognostic biomarker*Aberrant IGF1R/IRAIN expression ratio in cancer may serve as a biomarker for dysregulation of the IGF1R pathway

Beyond the preview

Go deeper on IGF1R antisense intragenic noncoding RNA (commonly known as IRAIN) (IRAIN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGF1R antisense intragenic noncoding RNA (commonly known as IRAIN) (IRAIN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call